NASDAQ:NMTR 9 Meters Biopharma (NMTR) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC Filings About 9 Meters Biopharma Stock (NASDAQ:NMTR) Get 9 Meters Biopharma alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume6 shsAverage Volume315,915 shsMarket Capitalization$1.04 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview 9 Meters Biopharma, Inc. was a clinical-stage biotechnology company focused on developing treatments for gastrointestinal and related metabolic disorders. The company’s research programs were aimed at conditions with limited therapeutic options, including celiac disease and short bowel syndrome. Its principal development programs included larazotide acetate, an investigational therapy designed to help regulate intestinal permeability in patients with celiac disease, and vurolenatide, an investigational long-acting peptide therapy studied for gastrointestinal disorders including short bowel syndrome. These products remained in development and were not established as broadly marketed commercial treatments. 9 Meters Biopharma was based in the United States and conducted its activities through clinical development and biotechnology research programs. John T. Temperato served as the company’s president and chief executive officer during its development-stage operations. Information about the company’s current operations and leadership may be limited because its public-company activities subsequently changed.AI Generated. May Contain Errors. Read More Receive NMTR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 9 Meters Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NMTR Stock News HeadlinesEnergy firms likely to miss smart meter deadline, warns Which?December 14, 2023 | bbc.comBDeal reached to sell some assets of bankrupt Raleigh firmNovember 8, 2023 | bizjournals.comFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets.October 16 at 1:00 AM | Weiss Ratings (Ad)9 Meters Biopharma, Inc. (NMTRQ)November 7, 2023 | finance.yahoo.com9 Meters Biopharma Inc (NMTRQ)October 17, 2023 | investing.com9 Meters Biopharma (OTC: NMTR.Q)August 16, 2023 | fool.comRaleigh firm joins worrying trend of bankruptcies for drugmakersJuly 18, 2023 | bizjournals.comDrug developer 9 Meters Biopharma files for bankruptcy protectionJuly 18, 2023 | reuters.comSee More Headlines NMTR Stock Analysis - Frequently Asked Questions How were 9 Meters Biopharma's earnings last quarter? 9 Meters Biopharma, Inc. (NASDAQ:NMTR) released its quarterly earnings data on Monday, November, 15th. The company reported ($1.00) earnings per share for the quarter, missing analysts' consensus estimates of ($0.74) by $0.26. When did 9 Meters Biopharma's stock split? Shares of 9 Meters Biopharma reverse split before market open on Tuesday, October 18th 2022.The 1-20 reverse split was announced on Tuesday, October 18th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 18th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of 9 Meters Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that 9 Meters Biopharma investors own include SNDL (SNDL), Tesla (TSLA), Tonix Pharmaceuticals (TNXP), NIO (NIO), Palantir Technologies (PLTR), Ocugen (OCGN) and FuelCell Energy (FCEL). Company Calendar Last Earnings11/15/2021Today10/16/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:NMTR CIK1551986 Webwww.9meters.com Phone(919) 275-1933FaxN/AEmployees20Year Founded2020Profitability EPS (Trailing Twelve Months)($3.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$43.77 million Net MarginsN/A Pretax MarginN/A Return on Equity-584.97% Return on Assets-159.45% Debt Debt-to-Equity RatioN/A Current Ratio0.59 Quick Ratio0.59 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.19 per share Price / BookN/AMiscellaneous Outstanding Shares14,336,000Free Float13,992,000Market Cap$1.04 million OptionableNo Data Beta1.36 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:NMTR) was last updated on 10/14/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredWhy Some AI Stocks Already Surged Over 300 PercentJason Bodner's system flagged Nvidia before a 7000 percent run, Super Micro Computer before a 2600 percent run...Brownstone Research | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredI'm giving you a space stock today. Free.On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any...Behind the Markets | SponsoredDid you grab your copy yet?Bill Poulos's Top 10 Stocks to Buy This Quarter report is still available free, but not for long. Every quarte...Profits Run | SponsoredBezos… DOOMED?A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 9 Meters Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 9 Meters Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
